Peptide Atlas · Peptide

Survodutide

Survodutide is a dual glucagon and GLP-1 receptor agonist; in a 48-week phase 2 trial in 293 adults with biopsy-confirmed MASH and fibrosis, MASH improved without fibrosis worsening in 43% to 62% on survodutide against 14% on placebo.

emerging

provisional
PubChem 171378821
1 citation
0 discussions
0 followers
BI 456906

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'Survodutide' with aliases BI 456906 · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
fact added identity: PubChem CID 171378821: CID 171378821, C192H289N47O61, 4232 g/mol. · 2026-09-27 12:04 · somebody
fact added identity: CAS registry number 2805997-46-8. · 2026-09-27 12:04 · somebody
fact added summary: Survodutide is a dual glucagon and GLP-1 receptor agonist; in a 48-week phase 2 trial in 293 adults with biopsy-confirme · 2026-09-27 12:04 · somebody
citation added pmid 38847460 cited as emerging: Survodutide improved MASH histology in a 48-week phase 2 trial · 2026-09-27 12:04 · somebody

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.